What is Hepatitis?

Get an overview of Hepatitis.

Help4Hep

A non-profit toll-free helpline

Donations

Help enhance our programs.

Home | Hepatitis C News

HEPATITIS C NEWS


    • After Being Cured…Can Hep C Return?
      READ NEWS
    • AbbVie Files NDA For All-Oral Hep C Regimen
      READ NEWS
    • Action Plan for the Prevention, Care and Treatment of Viral Hepatitis
      Building on the success of the nation’s first comprehensive cross-agency action plan, HHS released a 3-year update of the plan in April 2014. The updated plan builds on the foundation of the original action plan and seeks to harness:

        - New recommendations for health care providers regarding screening for hepatitis C;
        - Promising new developments in treatments for hepatitis C;
        - Mounting public awareness of and concern about hepatitis B and hepatitis C; and
        - The expansion of access to viral hepatitis prevention, diagnosis, care, and treatment offered by the Affordable Care Act.

      READ ABOUT AND DOWNLOAD THE 100 PAGE PLAN
    • New hepatitis C treatment very effective: Over 90 percent success rate in patients with cirrhosis
      READ NEWS
    • Hepatitis C Treatment Viable in Primary Care
      READ NEWS
    • Shorter Treatment Strategy Beats Hepatitis C
      READ NEWS
    • Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C
      READ NEWS
    • Future Data Anticipated from Abbvie's Clinical Trials Examines 3d Regimen with and Without Ribavirin, as Well as Treatment of Hepatitis C in Patients with Cirrhosis
      READ NEWS
    • Hepatitis C Treatment Viable in Primary Care
      READ NEWS
    • FDA OKs Major New Hepatitis C Drug, Sovaldi (Sofosbuvir)
      READ NEWS
    • OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
      READ NEWS
    • Hepatitis C Virus Maintains Infectivity for Weeks after Drying on Inanimate Surfaces at Room Temperature: Implications for Risks of Transmission
      READ NEWS
    • AASLD 2013: Long term survival of liver fibrosis after virological cure (SVR) in patients with chronic hepatitis C (CHC): The avenue of the scars?
      READ NEWS
    • Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naïve and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
      READ NEWS
    • AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks
      READ NEWS
    • AASLD 2013: Expanded Hepatitis C Screening Needed for Veterans, Baby Boomers, Pregnant Women
      READ NEWS
    • AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%
      READ NEWS
    • AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669
      READ NEWS
    • Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected with HIV
      READ NEWS
    • FDA Advisory Committee Supports Approval of Gilead’s Sofosbuvir for Chronic Hepatitis C Infection
      READ NEWS
    • Making Recovery Month Matter
      Service Improvement Blog brought to you by ATTC & NIATX
      VIEW BLOG
    • Virus C Hepatitis and Type 2 Diabetes: A Cohort Study in Southern Italy.
      READ NEWS
    • Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis.
      READ NEWS
    • Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
      READ NEWS
    • Gilead Submits New Drug Application to U.S. FDA For Sofosbuvir for the Treatment of Hepatitis C
      READ NEWS
    • As many as one in 50 people around the world is infected with some type of hepacivirus or pegivirus,
      including up to 200 million with hepatitis C virus (HCV), a leading cause of liver failure and liver cancer.
      READ NEWS
    • AMSTERDAM ‐‐ Two years after direct‐acting antiviral drugs for hepatitis C virus (HCV) infection hit the
      U.S. market, anemia has been far and away their most significant adverse effect, researchers said
      here.
      READ NEWS
    • AMSTERDAM, the Netherlands — A regimen of 3 direct-acting antiviral drugs plus ritonavir and
      ribavirin produced sustained virologic response rates in more than 90% of a broad range of patients
      infected with hepatitis C 24 weeks after therapy, results from a new clinical trial show.
      READ NEWS
    • Gilead Submits New Drug Application to U.S. Fda for Sofosbuvir for the Treatment Of Hepatitis C
      READ NEWS
    • Sustained Virological Response Linked With Improved Survival for HCV Patients
      READ NEWS
    • Adherence to hepatitis C treatment: unraveling the complexities
      READ NEWS
    • HCV Treatment Pipeline Update
      READ NEWS
    • The Hepatitis‐Fibromyalgia Connection
      READ NEWS
    • Serious and Fatal Skin Reactions to Incivek
      READ NEWS
    • Triple therapy has poor safety in cirrhotic hepatitis C
      BOSTON – In patients with chronic hepatitis C virus infections and compensated cirrhosis, a combination of a direct-acting antiviral agent, pegylated interferon, and ribavirin produced high on-treatment virologic response rates ...
      READ NEWS
    • Hepatitis C Reaching Crisis Levels; Requires Coverage for Routine Screenings
      WASHINGTON, Nov. 27, 2012 -- Summit on HIV and Viral Hepatitis Charts Priorities to Accelerate Testing, Reduce Disparities in Care
      READ NEWS
    • Abbott Announces Phase 3 Hepatitis C Program Details
      Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.
      READ NEWS
    • HCV Drug Combo Promising All on Its Own
      A three-drug regimen that eliminated both standard hepatitis C drugs has yielded positive early results in hard-to-treat patients, a researcher reported.
      READ NEWS
    • Simple HCV Regimen shows Promise
      A simplified hepatitis C (HCV) regimen with just two oral drugs had promising results in a difficult-to-treat population, a researcher reported here.
      READ NEWS
    • Gilead posts positive results in mid-stage Hepatitis C study
      (Reuters) - Gilead Sciences Inc on Saturday reported a 100 percent cure rate using a combination of drugs in a small number of patients with the most common and hardest to treat form of hepatitis C.
      READ NEWS
    • Abbott hepatitis C drugs bring high cure rates in trial
      (Reuters) - A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients, Abbott said on Saturday.
      READ NEWS
    • Washington Post Hepatitis & Liver Health Publication
      National media coverage is finally happening. Read the articles in this publication for concise information about hepatitis C, CDC recommendations that all baby boomers get tested and much more.
      READ NEWS
    • ATTAIN Study
      Clinical research doctors are looking for people with hepatitis C to participate in a clinical research study.
      READ NEWS
    • CDC Now Recommends All Baby Boomers Receive One-Time Hepatitis C Test
      New approach will help avert major increases in liver disease and deaths in the U.S.
      READ NEWS
    • DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity
      READ NEWS
    • Herbal & Dietary Supplements
      READ NEWS
    • Drug Interactions with Hepatitis C Virus NS3/4A Protease Inhibitors and HIV Medications: A Quick Guide for Clinicians
      READ NEWS
    • Telaprevir May Cause Severe Cutaneous Eruptions
      READ NEWS
    • EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
      READ NEWS
    • EASL: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
      READ NEWS
    • EASL: GS‐7977, Daclatasvir, and Asunaprevir Look Good in Interferon‐Free Regimens for Hepatitis C
      READ NEWS
    • Pancreatitis Forces Halt to HCV Drug Trial
      READ NEWS
    • High Cost of Telaprevir Overshadows Clinical Benefits in Patient Subset Results Based on Cost-Effectiveness Model
      READ NEWS
    • Updated AASLD HCV Guideline Aims To Simplify Use of DAAs: More Data Needed To Fill Gaps in Understanding
      READ NEWS
    • FDA Update Statin Labels Updated: HCV Protease Inhibitor Contraindication Highlighted
      READ NEWS
    • Federal Guidelines for the Treatment of Hepatitis C and Cirrhosis in Prisons 2012
      READ NEWS
    • The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings
      READ NEWS
    • Treatment of patients with chronic Hepatitis C Virus (HCV) infection with an interferon-free regimen
      READ NEWS
    • An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
      READ NEWS
    • HCV Protease Inhibitor Danoprevir Promising in Early Trial
      READ NEWS
    • DDW: Study Backs HCV Screens for All Boomers
      READ NEWS
    • Telemedicine Puts HCV Care in Hands of PCPs
      READ NEWS
    • Telaprevir (Incivek) Approved
      READ NEWS
    • BOCEPREVIR APPROVED
      READ NEWS
    • 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
      READ NEWS
    • First Sustained Response Data for Polymerase Inhibitor Mericitabine EASL
      READ NEWS
    • Pegylated Interferon Lambda Boosts Response with Few Side Effects EASL
      READ NEWS
    • Boceprevir Helps Hepatitis C Patients with Cirrhosis EASL
      READ NEWS
    • Statin Boosts Response to Pegylated Interferon/Ribavirin EASL
      READ NEWS
    • Liver Cancer in Cirrhotic Patients Effectively Treated With Radiofrequency Ablation, Study Suggests
      READ NEWS
    • HCV Infection and the Incidence of CKD
      READ NEWS
    • CDC Analysis Recommends Enhanced Acute Hepatitis C Surveillance
      READ NEWS
    • Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE
      READ NEWS
    • Non response to peginterferon alfa and ribavirin in IL28B CC & CT patients can be overcome by high dose continuous interferon alfa-2b administration in combination with ribavirin for chronic hepatitis C
      READ NEWS
    • GI-5005 Therapeutic Vaccine Plus Peg-IFN/Ribavirin Improves Sustained Virologic Response Versus Peg-IFN/Ribavirin In Prior Non-Responders With Genotype 1 Chronic HCV Infection
      READ NEWS
    • Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study
      READ NEWS
    • Response-Guided Therapy (RGT) with Boceprevir (BOC) + Peginterferon alfa-2b/Ribavirin (P/R) for Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype (G) 1 Was Similar to a 48-Wk Fixed-Duration Regimen with BOC + P/R in SPRINT-2
      READ NEWS
    • Completely individualized treatment durations with peginterferon-alfa-2b and ribavirin in HCV genotype 1-infected patients and importance of IL28B genotype (INDIV-2 study)
      READ NEWS
    • Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study
      READ NEWS
    • Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients with advanced chronic hepatitis C: extended follow - up results from the HALT - C Trial
      READ NEWS
    • FDA Issues Guidance for Development of Directing-acting Antiviral Drugs for Hepatitis C
      READ NEWS
    • Highest Rates of Hepatitis C Virus Transmission Found in Egypt
      READ NEWS
    • Vertex hep C drug works on many in 24 weeks: Study
      READ NEWS
    • KERRY & HONDA: Disrupting a deadly disease
      READ NEWS
    • Hispanics And Asians Less Likely To Receive Liver Transplants
      READ NEWS
    • FDA Approves Rapid Test for Antibodies to Hepatitis C Virus
      READ NEWS
    • Vitamin A and Treatment
      READ NEWS
    • Efforts to Up Minority Organ Donations Show Success
      READ NEWS
    • Study Finds Beta Blockers Alone More Effective for First Variceal Bleeding
      READ NEWS
    • Antiviral Therapy during Compensated Cirrhosis Most Cost-Effective Approach Treatment
      READ NEWS
    • Study Finds Poor Compliance with Cirrhosis Surveillance Recommendations Less than 20% of Qualified Patients Are Regularly Monitored
      READ NEWS
    • Peginterferon alfa-2B and Ribavirin for Liver Transplant Patients Yields 30% HCV SVR
      READ NEWS
    • Modest" Results With Nitazoxanide for HCV Genotype 1 Nonresponders
      READ NEWS
    • Study Links Liver Transplantation to Accelerated Cellular Aging
      READ NEWS
    • FDA Considers Expanded Use of HCV Drugs
      READ NEWS
    • Liver Donations from Living Donors Increase 42% after Educational Intervention
      READ NEWS
    • Infectious Disease Screening
      READ NEWS
    • Telaprevir Raises Response Rates in Hepatitis C
      READ NEWS
    • HCV Polymerase Inhibitor VX-222 Demonstrates Good Safety and Antiviral Activity in Treatment-naive Genotype 1 Hepatitis C Patients
      READ NEWS
    • HCV Protease Inhibitor Danoprevir (RG7227/ITMN-191) Shows Antiviral Activity at Lower Doses When Boosted with Ritonavir
      READ NEWS
    • HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse
      READ NEWS
    • Vertex Will Study All-Oral Regimen of HCV Protease Inhibitor Telaprevir plus Polymerase Inhibitor VX-222
      READ NEWS
    • U.S. Doctors Sanction Transplant Criteria for Liver Cancer Patients
      READ NEWS
    • Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies
      READ NEWS
    • Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
      READ NEWS
    • Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
      READ NEWS
    • Liver Donations from Living Donors Increase 42% after Educational Intervention
      READ NEWS
    • Vaccines May Lower Viral Load Improve Treatment Response
      READ NEWS
    • African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C
      READ NEWS
    • Metabolic Factors That Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV Patients
      READ NEWS
    • Weight Loss: A Modifiable Lifestyle Parameter That Can Alter HCV Liver Disease Progression
      READ NEWS
    • Silent Epidemic of Viral Hepatitis May Lead to Boom in Serious Liver Disease
      READ NEWS
    • Direct Antivirals Can Beat HCV Without Interferon
      READ NEWS
    • HCV Response Linked Strongly to Gene Variant
      READ NEWS
    • Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), An Investigational, Once-Daily Protease Inhibitor For Hepatitis C
      READ NEWS
    • More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen
      READ NEWS
    • Sprint 1 Study, Phase 2, Boceprevir
      READ NEWS
    • Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
      READ NEWS
    • Coffee Could Stall Liver Disease Progression
      READ NEWS
    • Hepatitis C Drug Development at a Crossroads - Comments from the Editors
      READ NEWS
    • Hypertension and Diabetes Are Concern in Long-Term Care of Liver Transplant Patients
      READ NEWS
    • The FDA has just issued new warnings in the package inserts for alpha interferons
      READ NEWS
    • Women, Blacks, Medicare Recipients Less Likely To Be Evaluated For Liver Transplantation
      READ NEWS
    • New Biomarker Predicts Response to Hepatitis C Treatment
      READ NEWS
    • Protein & Cholesterol May Increase Risk Of Cirrhosis & Hepatocellular Carcinoima
      READ NEWS
    • Weight-Related Factors Tied to Outcomes of Chronic Hepatitis C
      READ NEWS
    • Head-to-Head Trial Finds HCV Regimens Equal
      READ NEWS
    • Interferon and Ribavirin Second-Line Option for Hepatitis C
      READ NEWS
    • DDW: Interferon Has Long-Term Histo Benefits in HCV
      READ NEWS
    • FDA May Restrict Acetaminophen
      READ NEWS
    • Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1
      READ NEWS
    • DDW: Telaprevir Improves HCV Clearance in Resistant Patients
      READ NEWS
    • Hypothyroidism In Women Associated With Liver Cancer
      READ NEWS
    • Sustained Response Seen with New Hepatitis C Drug
      READ NEWS
    • Re-treatment of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated Interferon Alfa-2b (PegIntron)
      READ NEWS
    • Promising Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C
      READ NEWS
    • Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C
      READ NEWS
    • HCV Vaccine Development
      READ NEWS
    • Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
      READ NEWS
    • Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
      READ NEWS
    • Response To Therapy In Chronic Hepatitis C Predicted By 2-Day Results
      READ NEWS
    • Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
      READ NEWS
    • Hepatitis C Linked to Increased Risk of Intrahepatic Cholangiocarcinoma
      READ NEWS
    • Liver Biopsies Indicate Persistent Inflammation and Fibrosis in HCV Antibody Positive People with Undetectable HCV RNA
      READ NEWS
    • Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study with R7128 in Treatment Naive HCV Patients
      READ NEWS
    • Human Genome Sciences Announces Initiation of Phase 2b Trial 0f Albuferon Dosed Monthly in Chronic Hepatitis C
      READ NEWS
    • Although Hepatitis C Treatment Reduces The Virus, Liver Damage Continues
      READ NEWS
    • Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint In Phase 3 Trial In Chronic Hepatitis C
      READ NEWS
    • Pegylated interferon alpha2a is more effective in some hepatitis C patients with specific genotypes than the alpha2b form of the drug, an Italian researcher said
      READ NEWS
    • HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
      READ NEWS
    • Hepatitis C patients may have abnormal blood sugar
      READ NEWS
    • FDA Approves Nexavar for Patients with Inoperable Liver Cancer
      READ NEWS
    • Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years
      READ NEWS
    • Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
      READ NEWS
    • Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients
      READ NEWS
    • Insulin Resistance Independently Associated With Chronic Hepatitis C
      READ NEWS
    • Pathology of Chronic Hepatitis C in Children: Peds-C Trial
      READ NEWS
    • Silymarin (Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non Users
      READ NEWS
    • Acute Hepatitis C Infection and Spontaneous Viral Clearance in Adults and Children
      READ NEWS
    • How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50?
      READ NEWS
    • Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians
      READ NEWS
    • HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C
      READ NEWS
    • Use of Epoetin (EPO) to Manage Anemia in Chronic Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
      READ NEWS
    • Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis
      READ NEWS
    • HCV Care by Liver Specialists or Community-Based Practices: Pro & Con
      READ NEWS
    • Decreased HCV-specific Immunity in African-Americans May Help Explain Poorer Response to Antiviral Therapy
      READ NEWS
    • 400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV
      READ NEWS
    • Liver Stiffness Predicts Portal Hypertension in HCV Cirrhosis
      READ NEWS
    • EASL: Sustained Virologic Response Equals Cure for HCV Infection
      READ NEWS
    • Racial Differences Seen In Steatosis In Patients With Hepatitis C
      READ NEWS
    • New Vaccine Schedule Offers Protection Against Hepatitis A And Hepatitis B
      READ NEWS
    • Interferon Gamma Does Not Reverse Fibrosis in Hepatitis C Patients with Advanced Liver Disease
      READ NEWS
    • Hepatitis C in African Americans
      READ NEWS
    • Three Studies Examine Syringe Exchange Policies in the U.S.
      READ NEWS
    • Short-course Pegylated Interferon for Acute Hepatitis C
      READ NEWS
    • Heavy-Drinking Women with HCV Infection Cut Decade Off Life
      READ NEWS
    • Treatment Response in Cirrhotic Hepatitis C Patients with Portal Hypertension
      READ NEWS
    • Integrating Medical and Mental Health Care Improves Likelihood of Initiation and Adherence to Hepatitis C Treatment
      READ NEWS
    • Rapid Decline of HCV RNA in Patients Treated with VX-950
      READ NEWS
    • Predicting Survival After Liver Transplant
      READ NEWS
    • Patients Who Recover from Hepatitis C Have Lower Risk of Reinfection
      READ NEWS
    • New Therapy Significantly Increases Platelet Count
      READ NEWS
    • Is Hepatitis A and B Screening and Vaccination in Chronic Hepatitis C Patients Effective?
      READ NEWS
    • Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients
      READ NEWS

2013 Recovery Month Essay Contest: In My Own Words...

Vertex Patient Assistance for Incivek 855-837-8394 | www.incivek.com

Genentech Patient Assistance for
Pegasys & Copegus
| 888-941-3331

Merck Patient Assistance for Victrelis Peglntron & Rebetol
866-939-4372

Johnson & Johnson Patient
Assistance Foundation

800-652-6227 | www.jjpaf.org

Olysio Support (Medicare Excluded)
855-5-OLYSIO | www.olysio.com

Patient Access Network (PAN) Foundation for underinsured patients 866-316-PANF | www.panfoundation.org

Gilead Patient Assistance for Sovaldi
855-769-7284 | www.mysupportpath.com

Patient Assistance and GoodSearch Patient Assistance NOW and GoodSearch Patient Assistance NOW and GoodSearch

Home | What is hepatitis? | About Us | Who's Involved | Hepatitis C News | Upcoming Events | Brochures | Gift Cards | Related Links

Noteworthy Bulletins | All the Joy | Privacy Statement | Contact Information

© 2013 Hepatitis C Association Inc, All rights reserved.